

# PERIPHERAL NEUROPATHY – OVERVIEW OF ANATOMY AND PATHOLOGY

**Steven Scherer MD, PhD**  
The University of Pennsylvania

## **The cell types of the PNS**

The PNS is usually considered to be comprised of cell bodies and axons of motor, sensory, and autonomic neurons, and their associated glial cells (the Schwann cells and satellite cells that ensheath axons and cell bodies, respectively), and skeletal muscle. In addition, the neurons and glia of the enteric nervous system and all but one of the cranial nerves (the optic) are part of the PNS.

Motor neurons (motoneurons) innervate skeletal muscle fibers, and autonomic (sympathetic and parasympathetic) neurons innervate and regulate the function of secretory cells and smooth muscle cells.

Because skin and sensory nerves are typically biopsied, it is important to understand the diversity of sensory neurons, which can be distinguished by their function (Zimmermann et al., 2009), trophic dependence (Luo et al., 2009), and synaptic connections (Marmigere and Ernfors, 2007; Zampieri et al., 2014). For example, proprioceptors (IA afferents) innervate muscle spindles, have large myelinated axons, synapse on motoneurons, and depend on neurotrophin-3 signaling via their TrkC receptors for their normal development. Unmyelinated axons (C fibers) and thinly myelinated axons (A $\delta$ ) subserving nociception terminate in the superficial laminae of the spinal cord, and depend on NGF and/or neurturin signaling via their respective receptors (TrkA and c-ret) for their normal development. Mechanoreceptor sensory fibers (A $\alpha$ / $\beta$ ) innervating specialized sensory appendages (Merkel cells, Pacinian corpuscles, hair follicles, Meissner corpuscles) have precise connections in the dorsal horn of the spinal cord, and depend on a variety of trophic factors for their normal development (Table 1).

## **The myelin sheath**

In the mature peripheral nervous system, Schwann cells form myelin sheaths around most axons that are 1 micron in diameter or larger. All axons that innervate skeletal muscle (both intrafusal and extrafusal muscle cells) as well as a subset of sensory axons are myelinated. The bulk of the myelin sheath is formed by layer upon layer of closely apposed cell membranes, called compact myelin. The cell membrane itself is highly specialized, containing a higher proportion of lipids than typical cell membranes, as well as specialized lipids (galactocerebroside and sulfatide) and proteins (myelin protein zero; P0, peripheral myelin protein 22 kDa; PMP22) that are not found in most cell membranes. P0 is the “molecular glue” that holds together the apposed cell membranes. The function of PMP22 is unknown, but genetic evidence strongly suggests that precisely the right amount is required for the stability of the myelin sheath: halving the amount of PMP22 causes hereditary neuropathy with liability to pressure palsies (HNPP) and increasing the amount of PMP22 by one-half causes Charcot-Marie-Tooth disease type 1A (CMT1A).

A different set of molecular specializations characterize regions other parts of the myelin sheath – so-called “non-compact myelin”. Non-compact myelin is found in the paranodes (at the lateral edges of the myelin sheath) and incisures (funnel shaped disruptions of compact myelin). Non-compact myelin contains the molecules that form specialized junctions, including gap junctions that form a pathway for the diffusion of small molecules and ions directly across the myelin sheath. Mutations of the *GJB1*, the gene that encodes the gap junction protein connexin32, cause CMT1X, presumably because the mutant proteins do not form functional gap junctions in the myelin sheath.

### **Kinds of injury in the PNS**

The cells of the PNS can be injured:

Neurons. Neurons can be “injured” in a number of ways – toxins (e.g., too much B6), metabolic disorders (e.g., genetic causes of ALS), autoimmune disorders (sensory neuronopathy associated with small cell cancer), and physical injury (e.g., axonal injury near the cell body). For some causes, there appears to be a continuum between neuronopathy and neuropathy. In vitamin B6 intoxication, a large acute dose causes a sensory neuronopathy (Albin et al., 1987), whereas smaller, chronic doses produces an axonal sensory neuropathy (Xu et al., 1989). Selective cell death is typical. Motor neurons selectively die in spinal muscular atrophy and amyotrophic lateral sclerosis. Similarly, preganglionic autonomic neurons, post-ganglionic autonomic neurons, and sensory neurons are selectively affected in other diseases. Dead neurons are not replaced, but surviving neurons may be able to compensate if their terminals can sprout and effectively replace the terminals of the dead neurons.

Axons. A variety of genetic diseases, toxins, and acquired metabolic disorders (e.g., diabetes mellitus) damage axons, typically affecting the longest ones first, producing the clinical picture of length-dependent sensory and motor deficits. Trauma to peripheral nerves is less common kind of lesion, but has been best characterized injury owing to its reproducible nature in the laboratory animals. Axonal regeneration is possible in the PNS, but its success depends on the nature of the lesion (the continuity of the Schwann tubes is key) and the distance that axons must regenerate.

Myelinating Schwann cells. Injury to these cells usually results in demyelination (loss of myelin sheaths with preservation of axons), but does not typically cause cell death. Autoantibodies to one or more components of myelinating Schwann cells cause acquired demyelinating neuropathies (Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy), and mutations in the genes that encode various components of the myelin sheaths cause inherited demyelinating neuropathies (Charcot-Marie-Tooth disease). Remyelination is typically robust unless a genetic lesion compromises the Schwann cells themselves.

### **Axonal Neuropathies**

The physical length of axons may be the reason for their selective vulnerability – they are the longest cells in the body. Axons have a prominent cytoskeleton composed of intermediate filaments and microtubules. Because axonal protein synthesis is scant, proteins must be transported down the axon after they are synthesized in the cell body. Orthograde (from the cell body) axonal transport is mediated by microtubule-activated ATPases, known as kinesins, molecular motors that use microtubules as tracks; different kinesin transport different organelles.

A complex of dynein and p150 mediate retrograde axonal transport. Axons have plentiful mitochondria, which are presumably the main source of axonal ATP.

In most neuropathies, a progressive, “dying back” of the longest axons produces the clinical picture of a length-dependent neuropathy. The axonal loss is usually indolent and progressive, so that actively degenerating axons are rarely detected in nerve biopsies. Distal to the site of the “lesion”, myelinated axons are transformed into cords of Schwann cells that are not associated with any axons (bands of Büngner), and even these disappear with time, such that severe chronic neuropathies leave the nerves atrophied, with few Schwann cells and abundant collagen. Marked axonal with conspicuous myelin debris indicates that the neuropathy is acute – such as vasculitis and GBS.

Wallerian degeneration is the term that is used to describe the changes that occur in nerves distal to the site of a lesion (Scherer and Salzer, 2001). Although originally described for mechanically injured nerves, the same events appear to happen after toxic, metabolic, and genetic injuries to axons, and even after neuronal cell death. During Wallerian degeneration, the axon degenerates, which in turn, initiates the degeneration of myelin sheaths. The myelin sheaths break down and are phagocytosed, in part by Schwann cells, but also by the macrophages that invade the nerve. The basal lamina of the Schwann cell, however, remains intact and the Schwann cells remain within these basal lamina tubes. Previously myelinating, but now “denervated”, Schwann cells cease expressing the genes encoding components of myelin sheaths (proteins and glycolipids), and express genes that likely support regenerating axons.

Clusters of regenerated axons are found in some chronic neuropathies (CMT2, CMTX, and chronic vasculitis), but it is unlikely that these regenerating axons succeed in reaching their former targets.

Many sensory neurons (including those that convey pain information) and autonomic neurons (which innervate glands and smooth muscle) have unmyelinated axons. The term “small fiber neuropathy” denotes a neuropathy in which unmyelinated axons are selectively involved. With a few exceptions (e.g., Fabry disease), these are mostly acquired neuropathies, and chronic diabetes is the most common cause. In some kinds of Hereditary Sensory (and Autonomic) Neuropathies, unmyelinated axons are missing owing to the congenital loss of their associated cell bodies. In most small fiber neuropathies, the longest axons are affected first - the skin of the foot is denervated before the skin of the thigh.

### **Demyelinating Neuropathies**

Individual axons are myelinated nearly synchronously along their length, and the subsequent growth in that region of the body results in the elongation of myelin sheath. The axons destined to become the largest are the first to be myelinated; the smallest myelinated axons are the last to be myelinated. The result of these developmental processes is that the myelin sheaths (called internodes) of individual myelinated axons have remarkably similar lengths, and that the internodal lengths are linearly related to their axonal diameter. In addition, the myelin sheath and axon itself constitute about 40% and 60%, respectively, of the total diameter of the myelinated axon, regardless of the axonal diameter (this the basis of the “g-ratio” = diameter of axon/diameter of the myelinated fiber). If a myelin sheath breaks down, for whatever reason, the

demyelinated region is typically remyelinated. Because there is little turnover of myelin sheaths in normal nerves, abnormally thin myelin sheaths and abnormally short internodes are important pathological findings that are used to diagnose demyelinating neuropathies.

Most of the dominantly and recessively inherited demyelinating neuropathies also show evidence of repeated demyelination and remyelination, particularly the more severe forms, which are known as Dejerine-Sottas Neuropathy and Congenital Hypomyelinating Neuropathy. In these neuropathies, the “left over” Schwann cells (generated by proliferation during demyelination) that surround the remyelinated internode form “onion bulbs”. In addition to the demyelinating forms of CMT, de/remyelination is a feature of some dominant and recessive syndromes. Some inherited demyelinating neuropathies have particular pathological findings (Tables 2 and 3) – “tomacula” in HNPP, uncompacted myelin in some cases of CMT1B, “focally folded” myelin sheaths in CMT4B1 and CMT4B2, focal accumulations of glycolipids in lysosomes in the Schwann cells in metachromatic and globoid cell leukodystrophies.

Demyelination is also a feature of the demyelinating forms of GBS and of CIDP. In acute inflammatory demyelinating polyneuropathy (AIDP), complement is deposited on the outer surface of myelinating Schwann cells, followed by the vesicular degeneration of the outmost myelin lamellae (Hafer-Macko et al., 1996). In animal models, antibodies against the gangliosides GM1 (Susuki et al., 2007) and GD1a (McGonigal et al., 2010; Susuki et al., 2012) can disrupt the molecular architecture of the node in a complement-dependent manner. More recent work has shown that, in addition to gangliosides, antibodies against proteins that are localized in the nodal region may be the key for pathogenesis of GBS, CIDP, and acquired neuromyotonia (Table 4). Some of these antibodies are IgG4, which do not fix complement and likely cause demyelination in a complement-independent manner (Querol et al., 2014).

IgM kappa and IgG or IgA lambda paraproteins are associated with acquired demyelinating neuropathies. These paraproteins cause widening of compact myelin, presumably because they infiltrate it.

#### Selected references:

- Dyck PJ, Thomas PK, eds. (2005) *Peripheral Neuropathy*, 4th Edition. Philadelphia: Elsevier Saunders.
- Lazzarini RA, eds. (2004) *Myelin Biology and Disorders*. San Diego: Elsevier Academic Press.
- Midroni G, Bilbao JM (1995) *Biopsy Diagnosis of Peripheral Neuropathy*. Boston: Butterworth-Heinemann.
- Peters A, Palay SL, Webster HdeF (1991) *The Fine Structure of the Nervous System.*, 3rd Edition. New York: Oxford University Press.
- Schröder JM (2001) *The Pathology of Peripheral Nerves*. Berlin: Springer.
- Waxman SG, Kocsis JD, Stys PK, eds. (1995) *The Axon*. Oxford: Oxford University Press.

**Table 1.** Trophic factors for PNS neurons (with the help of Dr. Wenqin Luo).

Neuronal type	Trophic factor	Receptor
$\alpha$ -motoneurons	BDNF, NT-4 NT-3 LIF CNTF CT-1 CRLF1+CLCF1	TrkB TrkC LIF $\beta$ R+gp130 CNTFR $\alpha$ +gp130 CNTFR $\alpha$ +gp130 CNTFR $\alpha$ +gp130
$\gamma$ -motoneurons	GDNF	GFR $\alpha$ 1+ret
pre-ganglionic autonomic	NT-4 GDNF TGF-betas	TrkB GFR $\alpha$ 1+ret type I & II receptors
sympathetic	NGF artemin	TrkA GFR $\alpha$ 3+ret
parasympathetic	GDNF neurturin CRLF1+CLCF1	GFR $\alpha$ 1+ret GFR $\alpha$ 2+ret CNTFR $\alpha$ +gp130
trkA nociceptive	NGF	TrkA
IB4 nociceptive	NGF neurturin	TrkA (prenatal) GFR $\alpha$ 2+ ret (postnatal)
Merkel cells	NT3	TrkC
Pacinian corpuscles	neurturin	GFR $\alpha$ 2+ret
Meissner corpuscles	BDNF neurturin	TrkB GFR $\alpha$ 2+ret
A $\beta$ lanceolate endings	neurturin	GFR $\alpha$ 2+ret
A $\delta$ lanceolate endings	NT-4	TrkB
C lanceolate endings	NGF neurturin	TrkA (prenatal) GFR $\alpha$ 2+ ret (postnatal)
muscle spindle afferents	NT-3	TrkC

Table 2: Non-syndromic inherited neuropathies that have unique pathological findings. The table groups non-syndromic inherited neuropathies by their patterns of inheritance and phenotypes. Some diseases are thus listed more than once. The genes are named by the HUGO gene nomenclature (<http://www.genenames.org/>), and hyperlinked to this database. Dominant diseases are **bolded**. The diseases, their chromosomal locus, and genes are hyperlinked to OMIM (<http://www.ncbi.nlm.nih.gov/Omim/>).

Disease (OMIM)	Gene (OMIM)	Comments
CMT1 (autosomal or X-linked dominant demyelinating)		
<b>HNPP</b> (162500)	<a href="#">PMP22</a> (601097)	Tomacula superimposed on an underlying chronic, mild demyelinating neuropathy
<b>CMT1A</b> (118220)	<a href="#">PMP22</a> (601097)	Demyelinated axons are more prevalent in children; "hypomyelinated" axons are more numerous with age
<b>CMT1B</b> (118200)	<a href="#">MPZ</a> (159440)	Some mutations are associated with non-compact myelin; other have abnormally folded myelin sheaths
<b>CMT1X</b> (302800)	<a href="#">GJBI</a> (304040)	Chronic axonal neuropathy, with rudimentary onion bulbs and clusters of regenerated axons; unique pathology in the adaxonal Schwann cell cytoplasm
Autosomal recessive demyelinating neuropathy ("CMT4")		
<b>CMT4B1</b> (601382)	<a href="#">MTMR2</a> (603557)	Severe, demyelinating neuropathy, with irregular folding and redundant loops of myelin
<b>CMT4B2</b> (604563)	<a href="#">SBF2</a> (607697)	
<b>CMT4B3</b> (615284)	<a href="#">SBF1</a> (603560)	
<b>CMT4C</b> (601596)	<a href="#">SH3TC2</a> (608206)	Severe, demyelinating neuropathies
<b>CMT4D</b> (601455)1	<a href="#">NDRG1</a> (605262)	
<b>CMT4E</b> (605253)	<a href="#">EGR2</a> (129010)	
<b>CMT4F</b> (614895)	<a href="#">PRX</a> (605725)	
<b>CMT4H</b> (609311)	<a href="#">FGD4</a> (11104)	Severe, demyelinating neuropathy with outfolded myelin sheaths in the paranodal region
<b>CMT4J</b> (611228)	<a href="#">FIG4</a> (609390)	Severe, demyelinating neuropathies
<b>CMT4</b> (no OMIM)	<a href="#">PMP22</a> (601097)	
<b>CMT4</b> (no OMIM)	<a href="#">MPZ</a> (159440)	
Severe, demyelinating neuropathies; dominant or recessive		
Déjérine-Sottas neuropathy (145900)	Diverse genetic causes	Most biopsies show severe, demyelinating neuropathy. Some show endoneurial edema.
congenital hypomyelinating neuropathy (605253)	Diverse genetic causes	Some biopsies show an even greater paucity of myelin than DSN, and a failure of myelinating Schwann cells to progress beyond the promyelinating stage; some have "basal lamina onion bulbs".
CMT2 (autosomal dominant axonal) and dominant CMTX		
<b>CMT2E</b> (607684)	<a href="#">NEFL</a> (162280)	Masses of neurofilaments within axons
<b>giant axonal neuropathy 2</b> (610100)	<a href="#">DCAF8</a> (615820)	Masses of neurofilaments within axons
Autosomal recessive axonal neuropathy (ARCMT2)		
ARCMT2	<a href="#">NEFL</a> (162280)	Axons are small, and lack neurofilaments
Hereditary Sensory (and Autonomic) Neuropathy (HSN or HSAN)		
HSAN3 (223900)	<a href="#">IKBKAP</a> (603722)	Progressive loss of C-fibers and some myelinated fibers
HSAN4 (256800)	<a href="#">NTRK1</a> (191315)	C-fibers and small myelinated axons are congenitally absent
HSAN5 (608654)	<a href="#">NGF</a> (162030)	

Table 3: Syndromic inherited neuropathies that have unique pathological findings.. Dominant diseases are **bolded**. The genes are named according to the HUGO gene nomenclature (<http://www.genenames.org/>), and hyperlinked to this database. The diseases, their chromosomal locus, and genes are hyperlinked to OMIM (<http://www.ncbi.nlm.nih.gov/Omim/>).

Disease (OMIM)	Gene (OMIM)	Comments
Syndromic demyelinating neuropathies		
metachromatic leukodystrophy (250100)	<a href="#">ARSA (607574)</a>	lysosomal material in Schwann cells
globoid cell leukodystrophy (245200)	<a href="#">GALC (606890)</a>	lysosomal material in Schwann cells
gonadal dysgenesis with minifascicular neuropathy (607080)	<a href="#">DHH (605423)</a>	minifascicular neuropathy
Syndromic axonal neuropathies		
<b>FAP-1 (105210)</b> <b>FAP-2 (115430)</b>	<a href="#">TTR (176300)</a>	amyloid
<b>FAP-3 (105200)</b>	<a href="#">APOA1 (107680)</a>	
<b>FAP-4 (105120)</b>	<a href="#">GSN (137350)</a>	
<b>familial visceral amyloidosis (105200)</b>	<a href="#">B2M (109700)</a>	
<b>Somatic and autonomic neuropathy</b>	<a href="#">PRNP (176640)</a>	
giant axonal neuropathy-1 (256850)	<a href="#">GAN (605379)</a>	Masses of neurofilaments within axons
HP1 (259900)	<a href="#">AGXT (604285)</a>	intra-neural oxalate deposition
Fabry disease (301500)	<a href="#">GLA (300644)</a>	dark osmiophilic deposits in the perineurium and blood vessels
adrenoleukodystrophy (300100)	<a href="#">ABCD1 (300371)</a>	inclusions in Schwann cells
APBD (263570)	<a href="#">GBE1 (607839)</a>	polyglucosan bodies in axons
galactosialidosis (256540)	<a href="#">CTSA (613111)</a>	vacuoles in Schwann cells

APBD: polyglucosan body neuropathy, adult form;

FAP: familial amyloidotic polyneuropathy;

HP1: Hyperoxaluria, primary type 1

Table 4. Autoantibody against nodal proteins and associations with demyelinating diseases.

nodes		
gliomedin	GBS	(Devaux et al., 2012)
	CIPD	(Devaux et al., 2012)
Nr-CAM	GBS	(Devaux et al., 2012)
	CIPD	(Devaux et al., 2012)
moesin	GBS	(Sawai et al., 2014)
paranodes		
NF155	GBS	(Devaux et al., 2012; Kawamura and al., 2013; Ng et al., 2012; Pruss et al., 2011)
	CIDP	(Devaux et al., 2012; Kawamura and al., 2013; Ng et al., 2012; Querol et al., 2014)
	DADS	(Kawamura and al., 2013; Mathey et al., 2007)
	MMN	(Kawamura and al., 2013)
	CCPD	(Kawamura and al., 2013)
contactin	GBS	(Devaux et al., 2012; Doppler et al., 2015)
	CIDP	(Devaux et al., 2012; Doppler et al., 2015; Querol et al., 2014)
juxtaparanodes		
TAG-1	GBS	(Devaux et al., 2012)
	CIDP	(Devaux et al., 2012)
Caspr2	GBS	(Rosch et al., 2014; Tuzun et al., 2013)
	NMT	(Irani et al., 2010; Irani et al., 2012; Klein et al., 2012; Lancaster et al., 2011)

## References

- Albin, R.L., et al., 1987. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. *Neurology*. 37, 1729-1732.
- Devaux, J.J., Odaka, M., Yuki, N., 2012. Nodal proteins are target antigens in Guillain-Barre syndrome. *J. Periph. Nerv. Syst.* 17, 62-71.
- Doppler, K., et al., 2015. Destruction of paranodal architecture in inflammatory neuropathy with anti-contactin-1 autoantibodies. *J Neurol Neurosurg Psychiatry*.
- Hafer-Macko, C.E., et al., 1996. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. *Ann. Neurol.* 39, 627-637.
- Irani, S.R., et al., 2010. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. *Brain*. 133, 2734-2748.
- Irani, S.R., et al., 2012. Morvan syndrome: Clinical and serological observations in 29 cases. *Ann Neurol*. 72, 241-55.
- Kawamura, N., al., e., 2013. Anti-neurofascin antibody in patients with combined central and peripheral demyelination. *Neurology*. 81, 714-722.
- Klein, C.J., et al., 2012. Chronic pain as a manifestation of potassium channel-complex autoimmunity. *Neurology*. 79, 1136-44.
- Lancaster, E., et al., 2011. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. *Ann. Neurol.* . 69, 303-311.
- Luo, W.Q., et al., 2009. Molecular Identification of Rapidly Adapting Mechanoreceptors and Their Developmental Dependence on Ret Signaling. *Neuron*. 64, 841-856.
- Marmigere, F., Ernfors, P., 2007. Specification and connectivity of neuronal subtypes in the sensory lineage. *Nat Rev Neurosci*. 8, 114-27.



- Mathey, E.K., et al., 2007. Neurofascin as a novel target for autoantibody-mediated axonal injury. *J. Exp. Med.* 204, 2363-2372.
- McGonigal, R., et al., 2010. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. *Brain.* 133, 1944-1960.
- Ng, J.K., et al., 2012. Neurofascin as a target for autoantibodies in peripheral neuropathies. *Neurology.* 79, 2241-8.
- Pruss, H., et al., 2011. Neurofascin as target of autoantibodies in Guillain-Barre syndrome. *Brain.* 134, e173; author reply e174.
- Querol, L., et al., 2014. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. *Neurology.* 82, 879-886.
- Rosch, R.E., et al., 2014. Guillain-Barre syndrome associated with CASPR2 antibodies: two paediatric cases. *J Peripher Nerv Syst.*
- Sawai, S., et al., 2014. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barre syndrome. *Neurology.* 83, 113-7.
- Scherer, S.S., Salzer, J., 2001. Axon-Schwann cell interactions in peripheral nerve degeneration and regeneration. In: *Glial Cell Development*. Vol., K.R. Jessen, W.D. Richardson, ed.^eds. Oxford University Press, Oxford, pp. 299-330.
- Susuki, K., et al., 2007. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. *J Neurosci.* 27, 3956-67.
- Susuki, K., et al., 2012. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. *Exp Neurol.* 233, 534-42.
- Tuzun, E., et al., 2013. Guillain-Barre-like syndrome associated with lung adenocarcinoma and CASPR2 antibodies. *Muscle Nerve.* 48, 836-7.
- Xu, Y., Sladky, J.T., Brown, M.J., 1989. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. *Neurology.* 39, 1077-1083.
- Zampieri, N., Jessell, T.M., Murray, A.J., 2014. Mapping Sensory Circuits by Anterograde Transsynaptic Transfer of Recombinant Rabies Virus. *Neuron.*
- Zimmermann, K., et al., 2009. Phenotyping sensory nerve endings in vitro in the mouse. *Nat Protoc.* 4, 174-96.